MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birdsall, N. J. M.
Right arrow Articles by Sugimoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birdsall, N. J. M.
Right arrow Articles by Sugimoto, M.

Vol. 55, Issue 4, 778-786, April 1999

Subtype-Selective Positive Cooperative Interactions Between Brucine Analogs and Acetylcholine at Muscarinic Receptors: Functional Studies

Nigel J. M. Birdsall, Tim Farries,1 Parviz Gharagozloo, Shinsaku Kobayashi, Sebastian Lazareno, and Masahiko Sugimoto

Division of Physical Biochemistry, National Institute for Medical Research, London, UK (N.J.M.B.); Medical Research Council Collaborative Centre, London, UK (T.F., P.G., S.L.); Department of Pharmacology, Institute of Science and Technology Inc., Shinagawa-ku, Tokyo, Japan (S.K.); and Neuroscience Research Laboratories, Sankyo Co. Ltd., Shinagawa-ku, Tokyo, Japan (M.S.)

In radioligand binding studies, it has been reported that brucine, N-chloromethyl brucine, and brucine N-oxide increased the affinity of acetylcholine for M1, M3, and M4 muscarinic receptors, respectively, in a manner consistent with the predictions of the ternary complex allosteric model. We now demonstrate an equivalent ability of these three allosteric agents to modulate the actions of acetylcholine in functional studies in membranes and in whole cells. The enhancing actions of brucine and brucine N-oxide on acetylcholine (ACh) potency at M1 and M4 receptors respectively have been confirmed in guanosine-5'-O-(3-[35S]thio)triphosphate, GTPase, cAMP, and intracellular Ca2+ mobilization assays of function. In general, neither the basal nor the maximally stimulated response to ACh is affected. The subtype-selective allosteric effects of N-chloromethyl brucine on M2 and M3 receptors were shown to be qualitatively and quantitatively the same in guanosine-5'-O-(3-[35S]thio)triphosphate functional assays, in terms of both its affinity and cooperativity with ACh, as those found in binding assays. Neutral cooperativity of N-chloromethyl brucine with ACh on M4 receptor function was also observed, thereby demonstrating its "absolute subtype selectivity": a lack of action at any concentration at M4 receptors and an action at M2 and M3 receptors. The enhancing action of N-chloromethyl brucine on neurogenically released ACh binding at M3 receptors was also detected in whole tissue as an increased contraction of the isolated guinea pig ileum to submaximal electrical stimulation. In conclusion, these functional studies confirm that brucine analogs are allosteric enhancers of ACh affinity at certain muscarinic receptor subtypes.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Y. Chan, D. L. McKinzie, S. Bose, S. N. Mitchell, J. M. Witkin, R. C. Thompson, A. Christopoulos, S. Lazareno, N. J. M. Birdsall, F. P. Bymaster, et al.
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
PNAS, August 5, 2008; 105(31): 10978 - 10983.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz
Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling
Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Jakubik, A. Krejci, and V. Dolezal
Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Lanzafame and A. Christopoulos
Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 830 - 837.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Lazareno, V. Dolezal, A. Popham, and N. J. M. Birdsall
Thiochrome Enhances Acetylcholine Affinity at Muscarinic M4 Receptors: Receptor Subtype Selectivity via Cooperativity Rather than Affinity
Mol. Pharmacol., January 1, 2004; 65(1): 257 - 266.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Trankle, O. Weyand, U. Voigtlander, A. Mynett, S. Lazareno, N. J. M. Birdsall, and K. Mohr
Interactions of Orthosteric and Allosteric Ligands with [3H]Dimethyl-W84 at the Common Allosteric Site of Muscarinic M2 Receptors
Mol. Pharmacol., July 1, 2003; 64(1): 180 - 190.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Lazareno, A. Popham, and N. J. M. Birdsall
Analogs of WIN 62,577 Define a Second Allosteric Site on Muscarinic Receptors
Mol. Pharmacol., December 1, 2002; 62(6): 1492 - 1505.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Cheng, S. Khurana, Y. Chen, R. H. Kennedy, P. Zimniak, and J.-P. Raufman
Lithocholylcholine, a Bile Acid/Acetylcholine Hybrid, Is a Muscarinic Receptor Antagonist
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 29 - 35.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-G. Gao, S. G. Kim, K. A. Soltysiak, N. Melman, A. P. IJzerman, and K. A. Jacobson
Selective Allosteric Enhancement of Agonist Binding and Function at Human A3 Adenosine Receptors by a Series of Imidazoquinoline Derivatives
Mol. Pharmacol., July 1, 2002; 62(1): 81 - 89.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Zahn, N. Eckstein, C. Trankle, W. Sadee, and K. Mohr
Allosteric Modulation of Muscarinic Receptor Signaling: Alcuronium-Induced Conversion of Pilocarpine from an Agonist into an Antagonist
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 720 - 728.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Urwyler, J. Mosbacher, K. Lingenhoehl, J. Heid, K. Hofstetter, W. Froestl, B. Bettler, and K. Kaupmann
Positive Allosteric Modulation of Native and Recombinant gamma -Aminobutyric AcidB Receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its Aldehyde Analog CGP13501
Mol. Pharmacol., November 1, 2001; 60(5): 963 - 971.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Leppik and N. J. M. Birdsall
Agonist Binding and Function at the Human alpha 2A-Adrenoceptor: Allosteric Modulation by Amilorides
Mol. Pharmacol., November 1, 2000; 58(5): 1091 - 1099.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
R. A. Leppik, A. Mynett, S. Lazareno, and N. J. M. Birdsall
Allosteric Interactions between the Antagonist Prazosin and Amiloride Analogs at the Human alpha 1A-Adrenergic Receptor
Mol. Pharmacol., March 1, 2000; 57(3): 436 - 445.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
C. Tränkle, O. Weyand, A. Schröter, and K. Mohr
Using a Radioalloster to Test Predictions of the Cooperativity Model for Gallamine Binding to the Allosteric Site of Muscarinic Acetylcholine M2 Receptors
Mol. Pharmacol., November 1, 1999; 56(5): 962 - 965.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics